Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026)

Krystal Biotech has disclosed EBITDA Margin across 4 years of filings, most recently posting 45.7% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 45.7%, up 452.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 53.45% (up 1607.0% YoY), and the FY2025 annual result was 52.98%, up 2258.0% from the prior year.
• EBITDA Margin came in at 45.7% for Q1 2026 at Krystal Biotech, down from 48.03% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 942.04% in Q3 2023 to a low of 0.01% in Q1 2024.
• The 4-year median for EBITDA Margin is 41.18% (2025), against an average of 120.59%.
• Across the five-year window, EBITDA Margin plunged 90706 bps in 2024 and jumped 4611 bps in 2025, its largest moves.
• Krystal Biotech's EBITDA Margin stood at 23.05% in 2023, then surged by 108 bps to 48.05% in 2024, then decreased by 0 bps to 48.03% in 2025, then declined by 5 bps to 45.7% in 2026.
• The last three EBITDA Margin figures came in at 45.7% (Q1 2026), 48.03% (Q4 2025), and 81.09% (Q3 2025), per Business Quant data.